|1.||Bussel, James B: 13 articles (10/2015 - 11/2007)|
|2.||Theodore, Dickens: 9 articles (10/2015 - 11/2007)|
|3.||Brainsky, Andres: 9 articles (01/2015 - 12/2011)|
|4.||Cheng, Gregory: 7 articles (10/2015 - 11/2007)|
|5.||Stasi, Roberto: 7 articles (12/2010 - 12/2008)|
|6.||Giannini, Edoardo G: 6 articles (10/2015 - 09/2008)|
|7.||Mayer, Bhabita: 6 articles (01/2015 - 11/2007)|
|8.||Erickson-Miller, Connie L: 6 articles (12/2013 - 06/2007)|
|9.||Bailey, Christine K: 5 articles (10/2015 - 04/2009)|
|10.||Verma, Amit: 5 articles (10/2015 - 10/2009)|
12/01/2008 - "Randomized trials have shown the short-term efficacy of eltrombopag in elevating the platelet count of most adult patients with immune thrombocytopenia unresponsive to at least one standard treatment. "
03/01/2015 - "Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia."
01/01/2010 - "Based on the current and emerging evidence, a review of the pharmacologic basis, pharmacokinetics, therapeutic efficacy, safety profile and future considerations of eltrombopag in the context of HCV-related thrombocytopenia is given in this article. "
03/01/2010 - "Eltrombopag has shown promising results in the treatment of thrombocytopenia. "
03/01/2015 - "Eltrombopag: a new treatment option for chronic refractory adult immune thrombocytopenia."
01/01/2009 - "Eltrombopag therapy for 6 weeks also significantly decreased the incidence of WHO-defined bleeding compared with placebo. "
04/01/2013 - "Across all studies, bleeding at baseline ranged from 50 to 73% for eltrombopag-treated patients; by week 2, bleeding had decreased, ranging from 26 to 39%. "
02/21/2009 - "Patients receiving eltrombopag had less bleeding at any time during the study than did those receiving placebo (OR 0.49 [95% CI 0.26-0.89]; p=0.021). "
10/24/2015 - "Proportionately fewer patients who received eltrombopag (23 [37%] of 63 patients) had WHO grades 1-4 bleeding at the end of the double-blind period than did those who received placebo (16 [55%] of 29 patients); grades 2-4 bleeding were similar (three [5%] patients who received eltrombopag vs two [7%] patients who received placebo). "
09/10/2015 - "We asked whether eltrombopag, a thrombopoietic agent, would increase platelet counts, improve platelet activation, and/or reduce bleeding in WAS/XLT patients. "
|3.||Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune)
03/01/2014 - "Eltrombopag was suggested to be effective in perioperative management in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery. "
09/01/2012 - "Prolonged remission from eltrombopag in chronic refractory idiopathic thrombocytopenic purpura."
03/01/2014 - "[Effectiveness of perioperative administration of eltrombopag in a patient with idiopathic thrombocytopenic purpura undergoing cardiovascular surgery]."
01/01/2013 - "The authors' reply to Allen et al.: "A Comment on Boyers et al.: 'eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal'"."
01/01/2013 - "A comment on Boyers et al.: "eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal"."
|4.||Liver Diseases (Liver Disease)
04/01/2013 - "A summary of the preclinical studies and of studies carried out in patients with chronic liver disease with eltrombopag are presented in this paper. "
03/01/2014 - "To characterize the pharmacokinetics (PK)/pharmacodynamics (PD) of eltrombopag in chronic liver disease (CLD). "
03/01/2014 - "Population pharmacokinetic/pharmacodynamic modelling of eltrombopag in healthy volunteers and subjects with chronic liver disease."
04/01/2013 - "In chronic liver disease patients, the possible benefits of eltrombopag administration should be accurately weighed against the adverse events profile of the drug due to possible concerns regarding the occurrence of thromboembolic events and the potential for decompensation of chronic liver disease."
04/01/2013 - "Eltrombopag in patients with chronic liver disease."
10/01/2015 - "Demographic, clinical and genetic data collected from thrombocytopenic patients (n = 1463, age ≥ 18 years) with chronic HCV infection who were able to achieve a target platelet count of > 90 × 10(9) /L following eltrombopag treatment. "
10/01/2015 - "Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection."
06/01/2015 - "Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection."
07/01/2014 - "Eltrombopag for thrombocytopenic patients with chronic HCV infection."
01/01/2011 - "Ten patients responded to eltrombopag, and 4 of these patients experienced a transient loss of response following infection. "
|1.||Inosine Triphosphate (ITP)
|4.||Thrombopoietin (c-mpl Ligand)
|5.||Adrenal Cortex Hormones (Corticosteroids)
|6.||Intercellular Signaling Peptides and Proteins (Growth Factors)
|8.||4,5,6,7- tetrahydroisoxazolo(4,5- c)pyridin- 3- ol (THPO)
|1.||Hematopoietic Stem Cell Transplantation
|3.||Platelet Transfusion (Blood Platelet Transfusions)
|5.||Drug Therapy (Chemotherapy)